391 Long term follow-up of patients eligible, deferred, or ineligible for heart transplantation

2005 ◽  
Vol 4 (1) ◽  
pp. 87-87
Keyword(s):  
Heart Transplantation ◽  
Long Term Follow Up

De Novo Anti-HLA Antibodies After Heart Transplantation Are Associated With Adverse Events in the Long-term Follow-up of Cardiac Transplant Recipients

2016 ◽  
Vol 48 (9) ◽  
pp. 3030-3032 ◽  
Author(s):  
E. Solé-González ◽  
S. Mirabet ◽  
V. Brossa ◽  
L. López-López ◽  
M. Rivas-Lasarte ◽  
...  
Keyword(s):  
Adverse Events ◽  
Heart Transplantation ◽  
De Novo ◽  
Cardiac Transplant ◽  
Transplant Recipients ◽  
Hla Antibodies ◽  
Long Term Follow Up

scholarly journals The Predictive Value of Depression in the Years After Heart Transplantation for Mortality During Long-Term Follow-Up

2019 ◽  
Vol 81 (6) ◽  
pp. 513-520 ◽  
Author(s):  
Britta S. Bürker ◽  
Lars Gullestad ◽  
Einar Gude ◽  
Odd E. Havik ◽  
Anne Relbo Authen ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Predictive Value ◽  
Long Term Follow Up

scholarly journals Three decades of heart transplantation in Scandinavia: long-term follow-up

2013 ◽  
Vol 15 (3) ◽  
pp. 308-315 ◽  
Author(s):  
Göran Dellgren ◽  
Odd Geiran ◽  
Karl Lemström ◽  
Finn Gustafsson ◽  
Hans Eiskjaer ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Long Term Follow Up

scholarly journals Long-term follow-up after heart transplantation in very young children

2013 ◽  
Vol 106 (8-9) ◽  
pp. 463
Author(s):  
M. Veyrier ◽  
C. Ducreux ◽  
R. Henaine ◽  
A. Bozio ◽  
F. Sassolas ◽  
...  
Keyword(s):  
Young Children ◽  
Heart Transplantation ◽  
Very Young Children ◽  
Long Term Follow Up

Early aspirin initiation following heart transplantation is associated with reduced risk of allograft vasculopathy during long-term follow-up

2017 ◽  
Vol 31 (12) ◽  
pp. e13133 ◽  
Author(s):  
Yael Peled ◽  
Jacob Lavee ◽  
Eugenia Raichlin ◽  
Moshe Katz ◽  
Michael Arad ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Allograft Vasculopathy ◽  
Long Term Follow Up ◽  
Reduced Risk

Atrioventricular orthotopic heart transplantation: long term follow up of a prospective randomised clinical trial

2003 ◽  
Vol 22 (1) ◽  
pp. S171
Author(s):  
P.C Jansz ◽  
J.I Ferguson ◽  
K.K Dhital ◽  
J Wallwork ◽  
S.R Large
Keyword(s):  
Clinical Trial ◽  
Heart Transplantation ◽  
Randomised Clinical Trial ◽  
Orthotopic Heart Transplantation ◽  
Long Term Follow Up

Long-term follow-up of patients with tetralogy of Fallot and implantable cardioverter defibrillator

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
V Waldmann ◽  
A Bouzeman ◽  
G Duthoit ◽  
R Koutbi ◽  
F Bessiere ◽  
...  
Keyword(s):  
Primary Prevention ◽  
Secondary Prevention ◽  
Heart Transplantation ◽  
Implantable Cardioverter Defibrillator ◽  
Tetralogy Of Fallot ◽  
Icd Therapy ◽  
Cardioverter Defibrillator ◽  
Long Term Follow Up

Abstract Background Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart disease, and sudden cardiac death represents an important mode of death in these patients. Data evaluating the implantable cardioverter defibrillator (ICD) in this patient population remain scarce. Purpose We aimed to describe long-term follow-up of patients with TOF and ICD through a large nationwide registry. Methods Nationwide Registry including all TOF patients with an ICD initiated in 2010. The primary outcome was the first appropriate ICD therapy. Secondary outcomes included ICD-related complications, heart transplantation, and death. Clinical events were centrally adjudicated by a blinded committee. Cox proportional hazard models were used to identify predictors of appropriate ICD therapies and ICD-related complications. Results A total of 165 patients (mean age 42.2±13.3 years, 70.1% males) were included from 40 centers, including 104 (63.0%) in secondary prevention. During a median (IQR) follow-up of 6.8 (2.5–11.4) years, 78 (47.3%) patients received at least one appropriate ICD therapy, giving an annual incidence of 10.5% (7.1% and 12.5% in primary and secondary prevention, respectively, p=0.03). Overall, 71 (43.0%) patients presented with at least one complication, including inappropriate ICD shocks in 42 (25.5%) patients and lead/generator dysfunction in 36 (21.8%) patients. Among 61 (37.0%) primary prevention patients, the annual rate of appropriate ICD therapies was 4.1%, 5.3%, 9.5%, and 13.3% in patients with respectively no, one, two, or ≥ three guideline-recommended risk factors. In our cohort, QRS fragmentation was the only independent predictor of appropriate ICD therapies (HR 4.34, 95% CI 1.42–13.23), and its integration in a model with current criteria increased the area under the curve from 0.61 to 0.72 (p=0.006). No patient with left ventricular ejection fraction (LVEF) ≤35% without at least one other risk factor had appropriate ICD therapy. Patients with congestive heart failure and/or reduced LVEF had a higher risk of non-sudden death or heart transplantation (HR=11.01, 95% CI: 2.96–40.95). Conclusions Our findings demonstrate high rates of appropriate therapies in TOF patients with an ICD, including in primary prevention. The considerable long-term burden of ICD-related complications, however, underlines the need for careful candidate selection. A combination of easy-to-use criteria might improve risk stratification beyond low LVEF. Freedom from appropriate ICD therapy Funding Acknowledgement Type of funding source: None

REDUCED INCIDENCE OF HYPERURICEMIA, GOUT, AND RENAL FAILURE FOLLOWING LIVER TRANSPLANTATION IN COMPARISON TO HEART TRANSPLANTATION: A LONG-TERM FOLLOW-UP STUDY

2004 ◽  
Vol 77 (10) ◽  
pp. 1576-1580 ◽  
Author(s):  
Oren Shibolet ◽  
Eran Elinav ◽  
Yaron Ilan ◽  
Rifaat Safadi ◽  
Yaffa Ashur ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Renal Failure ◽  
Heart Transplantation ◽  
Follow Up Study ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document